Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally — revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug-response profiles and artificial intelligence-driven predictive modeling capabilities. . . . TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.”

To view the full article, visit http://ibn.fm/eFafn

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (domestic, international, clinical, CRO and D-CHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (“D-CHIP”) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Offers ‘Singular Solution’ in Growing Aerospace 3D-Metal-Printing Market

  • Aerospace 3D-printing market forecast to reach more than $3 billion in 2022
  • Industry expert calls in-process quality control “one of the most promising developments in metal ALM production”
  • SGLB technology represents paradigm shift in quality-control process for manufacturing of 3D-printed metal components

The additive marketing, or 3D printing, industry is flying high in the aerospace sector. A Research and Markets study reported the aerospace 3D printing market is expected to grow from $714.5 million in 2017 to $3,057.9 billion by 2022 — a CAGR of 27.42% (http://ibn.fm/ly23w). Those numbers could go even higher as quality-assurance obstacles that have impeded the full adoption of 3D metal printing are successfully eliminated by Sigma Labs Inc. (NASDAQ: SGLB), the only provider of in-process, quality-assurance software to the commercial 3D-metal- printing industry.

“Aerospace has a long history of latest technology inventions’ early adopter and ultimate trendsetter in manufacturing,” according to an article by Farinia Group – a manufacturing organization dedicated to material transformation using state-of-the art equipment, know-how and technical expertise (http://ibn.fm/qeUsL). “New materials, state-of-the-art manufacturing processes and sophisticated software were created and absorbed by this industry decades ago and are now common for other industries.”

The Farinia Group noted several advantages of 3D printing in the aerospace sector, including the following:

  • Shorter development process and time to market
  • Freedom to design complex geometries, leading to maximized performance, consolidated design, improved reliability, and improved fuel efficiency
  • On-demand and on-site spares manufacturing
  • Higher material efficiency
  • Reduced costs for certain components
  • In-process quality assurance reducing overall lead time

It is in this last area – in-process quality assurance – where Sigma Labs shines. The company’s proprietary PrintRite3D® software is the singular solution that enables real-time, in-process detection of manufacturing irregularities for critical metal parts. The technology then provides the operator with the information and ability to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality-control process for the manufacture of 3D printed metal components. The company is the only provider of in-process quality-assurance software to the commercial 3D-metal-printing industry offering these capabilities.

“Aerospace, as an industry obsessed by performance and reliability, has since long performed quality-assurance downstream to manufacturing,” the Farinia Group article continues. “A critical stage for aerospace manufacturers in which any serial production often have to meet high specifications to satisfy stringent applications with high quality to ensure reliability. Insomuch that quality assurance can account significantly in the overall lead time and overall cost.”

In its report, the Farinia Group noted that “one of the most promising developments in metal ALM (additive layer manufacturing) production systems concerns the real-time and closed-loop in-process quality control…Monitoring the system settings and process parameters during the ongoing manufacturing permits to regulate and optimize conditions… In-process inspection of the material health and dimensional accuracy will surely unlock the power of ALM technology for serial aerospace production as qualification and consistency variation are now the main concerns.”

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D advanced manufacturing technologies. SGLB’s advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production – uniquely allowing errors to be corrected in real time.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) Awarded Contract by Leading Research Institution Mississippi State University Center for Advanced Vehicular Systems

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been awarded a contract by the Mississippi State University Center for Advanced Vehicular Systems (“CAVS”), a world-class interdisciplinary research center that uses state-of-the-art technology to address engineering challenges facing U.S. mobility industries. Per the update, CAVS will install PrinteRite3D on a Renishaw AM400 machine, a new OEM platform for Sigma Labs, further proving the interoperability potential of PrintRite3D’s platform to an increasingly large machine base. Under the agreement, in addition to any PrintRite3D(R) research or commercial applications, CAVS has agreed to serve as a real-world test bed for new product improvements that Sigma will deploy over time. “The Research & Development and University sectors of the additive manufacturing (“AM”) market is important to Sigma as we expand our footprint in the retail market segment with another contract win with the Mississippi State University Center for Advanced Vehicular Systems, a leading research institution and thought leader,” Sigma Labs Executive Chairman Mark K. Ruport said in the news release. “They have agreed to act as a test bed for new product improvements to PrintRite3D(R), uniquely allowing us a real-world feedback loop to continuously improve our technology suite. I look forward to working with the entire team at CAVS to bring a new level of quality assurance to both their partners and the additive manufacturing industry as a whole.”

To view the full press release, visit http://ibn.fm/jFSBq

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enhances Cannabis Products’ Shelf-Life Potency, Addressing Industry Distribution Challenges

  • Many cannabis companies have struggled with declining investor interest amid product delivery shortfalls and adverse revenue reports
  • The distribution obstacles have exacerbated company concerns by creating choking points for inventory, which can quickly lose potency in storage
  • Lexaria Bioscience’s trademarked DehydraTECH powder-creating technology helps preserve cannabinoid effectiveness and extend storage potential 2 to 3 years
  • The DehydraTECH platform also provides a key benefit in making cannabinoids, nicotine, NSAIDs and other drug products bioavailable as rapidly as inhaled products
  • An alternative to inhaled smokes and vapes could provide health and wellness benefits to consumers by eliminating harm to users’ lungs
  • Lexaria’s licensing strategy also enables other companies to utilize DehydraTECH’s IP in their products

As the cannabis industry works to weather 2019’s adverse profit and productivity reports (http://ibn.fm/niYkO), consumption drug platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping to ensure that product inventories can remain potent and perform at their potential despite a natural tendency for cannabinoids to deteriorate with time.

Public market investors have been short-term allies in a fledgling industry seeking long-term commitment, in large part because of initial sky-high expectations for profits from cannabis-related industries and regulatory hurdles from government oversight of a once-illegal product that have kept the brakes on runaway commerce. As a result, many companies have built up outsized debt-revenue ratios (http://ibn.fm/G29Ig).

Added to those concerns, a European study determined that the potency of tetrahydrocannabinol (THC) and cannabidiol (CBD) tends to degrade over time – THC by 20 percent per year while in storage and CBD by 10 percent (http://ibn.fm/3Dj6d), ensuring a need for producers to get their products to market in a timely fashion. Additionally, a study of storage mediums used for THC found that certain types of packaging can contribute to the degradation of the extract’s potency (http://ibn.fm/w0INv).

The adverse factors have combined to create a potential source of caution among consumers as some companies have had to report multi-million-dollar losses due to “congested inventory channels” resulting from production that has exceeded sales (http://ibn.fm/gbogP).

Lexaria’s product-stabilizing DehydraTECH(TM) oral drug delivery IP turns cannabis and hemp oils into powders that preserve the cannabinoid extracts in the products while mitigating microbiological growth to help the products last longer on retail shelves – the company reports (http://ibn.fm/KEyQ4) that products can be stored for two to three years and experience “reduced loss of cannabinoids compared to current industry practices.”

DehydraTECH’s primary benefit is that it enables swallowed drug substances to deliver their intended effects as rapidly and effectively as inhaled products such as smokes or vapes. Many consumers continue to prefer inhaling products containing nicotine-rich tobacco or cannabis-based marijuana and CBD, acknowledging that they get a quicker, better response than if they try to use other medicinal/wellness delivery methods.

The dangers of inhaling drug substances into the lungs have been established over decades, with recent concerns about vape ingredients adding new fuel to the fire (http://ibn.fm/ncC40). Lexaria is committed to combatting the deleterious effects of drug inhalation by making swallowed drug products more rapidly bioavailable in the bloodstream, and thereby as attractive as inhaled products if not more so.

In addition to the DehydraTECH products Lexaria markets, the company also licenses its technology to other companies for them to use in all of their edible and topical cannabis and/or hemp extract processing needs. Lexaria is able to process 250,000 servings of CBD at 10 mg each per day currently for distribution across the country.

Although CBD-based wellness products continue to remain under scrutiny by the federal government, many states have legalized topical and edible uses. A recent licensing agreement between Lexaria and the smokeless Cannadips CBD brand is drawing on DehydraTECH’s IP for a product chain available nationally through Circle K convenience outlets, in about 5,000 stores throughout the United States.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Youngevity International Inc.’s (NASDAQ: YGYI) CLR Roasters Forges New Distribution Partnership with Prestigious Distributor Krasdale Foods

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments, today announced that its wholly-owned subsidiary CLR Roasters has forged a new distribution partnership with prestigious distributor Krasdale Foods. In the business for over 100 years, Krasdale Foods distributes over 12,000 grocery item SKUs, services over 2500 retail locations and its geographic footprint includes NYC and metro areas in New York, as well as New Jersey, Connecticut, Pennsylvania, Massachusetts, and Rhode Island. Krasdale Foods plans to begin distribution of Café La Rica next month, with, in the first week of March, an initial stocking order of Café La Rica’s gourmet espresso shipping from CLR Roasters to Krasdale’s Bronx, NY-based distribution facility. “We are proud to see CLR’s Flagship brand, Café La Rica, pick up such a significant and prestigious distribution partner” Youngevity President and CFO Dave Briskie said in the news release. “We expect the continuation of this partnership to help drive the continued growth of our Café La Rica brand throughout 2020.”

To view the full press release, visit http://ibn.fm/NA8Oo

About Youngevity International

Youngevity International, Inc. (NASDAQ : YGYI ) is an multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise.  The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Youngevity International Inc. YGYI | Leave a comment

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Announces Q2 Fiscal 2020 Results

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) on Monday released its results for the period ended December 28, 2019. According to the update, Green Growth Brands’ revenues for the period totaled $21.1M. “The results this quarter are a reflection of our ability to create products and experiences that consumers want,” Green Growth Brands CEO Peter Horvath said in the news release. “We are pleased with the consumer demand signals we saw in the CBD segment during the quarter, and we remain confident in its future potential. However, overhead costs, near-term obligations and constraints on liquidity have posed significant challenges that have hindered us from growing the CBD business in the timeframes we anticipated to its full-potential. The initiatives we announced today to sell the CBD segment, restructure debt and raise equity financing improves the financial infrastructure we need to scale our MSO segment. We believe focusing our expertise on the MSO segment will yield the highest long-term value for our shareholders and customers.”

To view the full press release, visit http://ibn.fm/oAbQO

About Green Growth Brands Inc.

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and 8 Fold. The Company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. Learn more about the vision at GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Green Growth Brands Inc. GGBXF, MissionIRNewsBreaks | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

  • POAI subsidiary announces new media for growing ovarian tumors in lab
  • Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers
  • New media available as cell-culture market expected to reach $2.3 billion by 2024

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://ibn.fm/QjW3K). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers and precision therapies.

“Using these proprietary media, our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis President Richard Gabriel stated in a news release. “The resulting cells have a 95+% match to cells found in patient bodies.”

The timing of POAI’s announcement couldn’t be better. Experts predict that the global cell-culture media market will reach $2.3 billion by 2024. That growth – a steady 8.4% CAGR – is primarily fueled by the increased use of biological-based drugs such as immune therapies, a space where POAI and its subsidiaries are establishing themselves as both leaders and pioneers.

POAI anticipates that the new media will be available Q1 2020 through Massachusetts-based US Biological, a primary brand for the life-science industry. United States Biological’s biochemicals, antibodies, recombinant proteins, cell-culture media and molecular biology kits are used in virtually all scientific applications and settings including genomic research, biotechnology, pharmaceutical development and the diagnosis of disease.

Traditionally, cell-culture media selects for only one or two fast-growing cell types, so the ability to identify 25 different cell types is a significant advancement. The proprietary media developed by TumorGenesis are designed specifically to assist researchers in isolating and maintaining the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory.

“We believe by helping researchers develop cells and tumors that more closely mimic cells and tumors found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” said Gabriel. Acknowledging that specialty media comprises only a small subset of the market, Gabriel explained that TumorGenesis sees this initial ovarian-specific formulation as the first in what the company anticipates being a long line of tools and services it will offer to cancer researchers.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) to Present at LD Micro Virtual Investor Conference on March 4

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that management will present at the LD Micro Virtual Investor Conference at 1:00 p.m. Eastern Time on March 4, 2020. According to the update, Sigma Labs Executive Chairman, Mark K. Ruport, will present an overview of the business model and growth initiatives. A presentation will accompany the webinar, which will be followed by a question and answer session.

To access the webinar, visit http://ibn.fm/jnPJz

To view the full press release, visit http://ibn.fm/wiiaV

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Trxade Group, Inc. (NASDAQ: MEDS) Announces Underwriters Exercise of Overallotment Option

Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, today announced the exercise by the underwriters of the Company’s previously announced firm commitment underwritten offering which closed on February 18, 2020. According to the update, the exercise of the overallotment option and the underwriters purchase of 115,767 shares of common stock, each at the public offering price of $6.50, less the underwriters’ discount of $0.52 per share, resulted in net pricing of $5.98 per share. Trxade Group received approximately $0.7 million in gross proceeds from the sale of common stock from the underwriters’ exercise of their overallotment option, prior to deducting offering expenses. Trxade Group intends to use the net proceeds for working capital and general corporate purposes and possibly to fund acquisitions of other companies, products or technologies.

To view the full press release, visit http://ibn.fm/JujfJ

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy delivery capabilities using DelivMeds app. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Trxade Group Inc. (MEDS) | Leave a comment

MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Major CPG Company’s Results to Generate 6 to 1 ROAS and 4.5% Incremental Sales Lift Through Employment of BIGtoken

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announced the release of a new case study. According to the update, the study illustrates results when one of the largest global food and beverage companies activated BIGtoken to drive sales during the 2019 holiday season. The campaign featured opt-in panels and BIGtoken platform offers, whereby users answered questions about the brand and category, scanned receipts and shared other data points about their consumer journey. The high-value insights were then used to create audiences and messaging strategy pre-activation, as well as optimize against these insights throughout the program. The consumer-packaged goods (“CPG”) company increased its incremental sales by 4.5% and generated a return on ad spend (“ROAS”) of 6 to 1 as a result of employing BIGtoken. “It’s becoming critical for brands to partner with systems that put emphasis on consumer-first data particles and put consumers’ data rights at the forefront,” VP of BIGtoken Brands George Stella said in the news release. “The biggest brands in the world are adopting BIGtoken’s first-party, opt-in data platform as the next generation system that addresses data accuracy and regulations.”

To view the full press release, visit http://ibn.fm/E31OL

About SRAX

SRAX, Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, SRAX, Inc. SRAX | Leave a comment